SlideShare a Scribd company logo
1 of 14
CHANGES AFOOT: A NEW MODEL
OF INTERACTION BETWEEN
DOCTORS AND ENGAGED
PATIENTS
H. Jack West, MD
Swedish Cancer Institute
Seattle, WA
Global Resource for Advancing Cancer Education
(GRACE)
www.cancerGRACE.org
The Unidirectional Model

Requires:
•a finite amount of medical information
•only the physician having access to it
NOBODY Can Keep Up with the
Torrent of New Medical Information
• Rate of new content more
than doubling in last 20 yrs
• More & more journals,
especially in oncology (>180)

(courtesy of Jason Priem/blog)
No wonder it feels overwhelming
Before and After Molecular Oncology
Before

After

Large populations

Small Populations

Marginal effects

Major benefits

Trials in hundreds of sites

Trials in very few sites

Generally rely on
oncologists to enroll

May well fall to patients
and caregivers to seek out
25%
2000

81%
2011
Physicians may be concerned about
losing control over the discussion
Physicians remain the most trusted
source of information about medical
issues

From Fox, Peer to Peer Healthcare,
Pew Internet and American Life Project, 2011
www.CancerGRACE.org
a 501(c)3 nonprofit
Bidirectional Model
Network Model
Patients are HIGHLY MOTIVATED
to help themselves

www.CancerGRACE.org
a 501(c)3 nonprofit
Adapting to a new model:
Disruption comes with opportunities
• Relationships between patients and physicians
are changing

• Bidirectional
• Physicians no longer expected to know everything
out there to know
• Patients/caregivers will increasingly turn to social
networks and searchable online content

www.CancerGRACE.org

• Physicians will have a critical role, even if it
a 501(c)3 nonprofit
changes fundamentally in coming years

More Related Content

What's hot

Hannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in GenomicsHannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in GenomicsHannes Smárason
 
ROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONS
ROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONSROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONS
ROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONSAnaivko
 
Personalized Medicine: The Future is Almost Here
Personalized Medicine: The Future is Almost HerePersonalized Medicine: The Future is Almost Here
Personalized Medicine: The Future is Almost HereHannes Smárason
 
Virtual tumor boards for remote patient oncology
Virtual tumor boards for remote patient oncologyVirtual tumor boards for remote patient oncology
Virtual tumor boards for remote patient oncologyJim Smurro
 
Goran Panel Goran
Goran Panel GoranGoran Panel Goran
Goran Panel GoranIDS
 
MassTLC BCBSMA, Dana Safran Analytics presentation
MassTLC BCBSMA, Dana Safran Analytics presentationMassTLC BCBSMA, Dana Safran Analytics presentation
MassTLC BCBSMA, Dana Safran Analytics presentationMassTLC
 
Why is HCV medication not available to all?
Why is HCV medication not available to all?Why is HCV medication not available to all?
Why is HCV medication not available to all?IDHDP
 
Why is Naloxone that prevent so many overdose deaths not always available at ...
Why is Naloxone that prevent so many overdose deaths not always available at ...Why is Naloxone that prevent so many overdose deaths not always available at ...
Why is Naloxone that prevent so many overdose deaths not always available at ...IDHDP
 
Hannes Smarason: Genomics: Forging Patient-Centric Communities
Hannes Smarason: Genomics: Forging Patient-Centric CommunitiesHannes Smarason: Genomics: Forging Patient-Centric Communities
Hannes Smarason: Genomics: Forging Patient-Centric CommunitiesHannes Smárason
 
How do physicians view the affordable care act?
How do physicians view the affordable care act?How do physicians view the affordable care act?
How do physicians view the affordable care act?leadingphysicianofworld
 
Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...
Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...
Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...Sunil Nair
 
Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...
Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...
Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...Hannes Smárason
 
Ovarian Cancer Research Fund Enables Breakthroughs in Saving Lives
Ovarian Cancer Research Fund Enables Breakthroughs in Saving LivesOvarian Cancer Research Fund Enables Breakthroughs in Saving Lives
Ovarian Cancer Research Fund Enables Breakthroughs in Saving LivesHaberman Management Corp
 

What's hot (20)

TH Jan 2016 v3
TH Jan 2016 v3TH Jan 2016 v3
TH Jan 2016 v3
 
Hannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in GenomicsHannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in Genomics
 
Using technology to improve quality
Using technology to improve qualityUsing technology to improve quality
Using technology to improve quality
 
ROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONS
ROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONSROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONS
ROLE OF LIBRARIAN IN HEALTH CARE INSTITUTIONS
 
John-Peter Bradford, Life-Savings Therapies Network
John-Peter Bradford, Life-Savings Therapies Network John-Peter Bradford, Life-Savings Therapies Network
John-Peter Bradford, Life-Savings Therapies Network
 
Personalized Medicine: The Future is Almost Here
Personalized Medicine: The Future is Almost HerePersonalized Medicine: The Future is Almost Here
Personalized Medicine: The Future is Almost Here
 
Virtual tumor boards for remote patient oncology
Virtual tumor boards for remote patient oncologyVirtual tumor boards for remote patient oncology
Virtual tumor boards for remote patient oncology
 
Goran Panel Goran
Goran Panel GoranGoran Panel Goran
Goran Panel Goran
 
MassTLC BCBSMA, Dana Safran Analytics presentation
MassTLC BCBSMA, Dana Safran Analytics presentationMassTLC BCBSMA, Dana Safran Analytics presentation
MassTLC BCBSMA, Dana Safran Analytics presentation
 
Initial Medical Policy and Model Coverage Guidelines
Initial Medical Policy and Model Coverage GuidelinesInitial Medical Policy and Model Coverage Guidelines
Initial Medical Policy and Model Coverage Guidelines
 
Why is HCV medication not available to all?
Why is HCV medication not available to all?Why is HCV medication not available to all?
Why is HCV medication not available to all?
 
Why is Naloxone that prevent so many overdose deaths not always available at ...
Why is Naloxone that prevent so many overdose deaths not always available at ...Why is Naloxone that prevent so many overdose deaths not always available at ...
Why is Naloxone that prevent so many overdose deaths not always available at ...
 
Hannes Smarason: Genomics: Forging Patient-Centric Communities
Hannes Smarason: Genomics: Forging Patient-Centric CommunitiesHannes Smarason: Genomics: Forging Patient-Centric Communities
Hannes Smarason: Genomics: Forging Patient-Centric Communities
 
How do physicians view the affordable care act?
How do physicians view the affordable care act?How do physicians view the affordable care act?
How do physicians view the affordable care act?
 
Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...
Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...
Personalized Disease Management - Thyroid Cancer - Knowledge Management - Sun...
 
Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...
Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...
Maintaining Momentum Post-­ASHG 2014: Maximizing the Value of Large Genomic D...
 
RAHD Poster_LR
RAHD Poster_LRRAHD Poster_LR
RAHD Poster_LR
 
Ovarian Cancer Research Fund Enables Breakthroughs in Saving Lives
Ovarian Cancer Research Fund Enables Breakthroughs in Saving LivesOvarian Cancer Research Fund Enables Breakthroughs in Saving Lives
Ovarian Cancer Research Fund Enables Breakthroughs in Saving Lives
 
Lean london lachman_talk
Lean london lachman_talkLean london lachman_talk
Lean london lachman_talk
 
Towse future of CER in US
Towse future of CER in USTowse future of CER in US
Towse future of CER in US
 

Viewers also liked

Fluke Test Tools Catalog 2010/2011
Fluke Test Tools Catalog 2010/2011Fluke Test Tools Catalog 2010/2011
Fluke Test Tools Catalog 2010/2011FlukeinMalta
 
Zend cache evolution.владимир дубина
Zend cache   evolution.владимир дубинаZend cache   evolution.владимир дубина
Zend cache evolution.владимир дубинаAndrey Tokarchuk
 
Lectores y escritores
Lectores y escritoresLectores y escritores
Lectores y escritoresLusy Chisag
 
Competències, canvi curricular i millora educativa: una relació problemàtica
Competències, canvi curricular i millora educativa: una relació problemàticaCompetències, canvi curricular i millora educativa: una relació problemàtica
Competències, canvi curricular i millora educativa: una relació problemàticaICE_URV_NU
 
Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...
Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...
Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...newcastlegateshead
 
December 2013- Industry Insights - Leadership survey
December 2013- Industry Insights - Leadership surveyDecember 2013- Industry Insights - Leadership survey
December 2013- Industry Insights - Leadership surveyConfiance Australia
 
Mod de viata sanatos 2
Mod de viata sanatos 2Mod de viata sanatos 2
Mod de viata sanatos 2Pishta Bmc
 
Chapter 10 presentation
Chapter 10 presentationChapter 10 presentation
Chapter 10 presentationdesntay2
 
Struts1+ hibernate3
Struts1+ hibernate3Struts1+ hibernate3
Struts1+ hibernate3edanwade
 
Chapter 12 presentation
Chapter 12 presentationChapter 12 presentation
Chapter 12 presentationdesntay2
 
Exportaciones y Emprendimiento
Exportaciones y EmprendimientoExportaciones y Emprendimiento
Exportaciones y EmprendimientoAREX Lambayeque
 
Sujith cv[1][1][1](2)1
Sujith cv[1][1][1](2)1Sujith cv[1][1][1](2)1
Sujith cv[1][1][1](2)1sujiththambi
 
Fcds mid term 3
Fcds mid term 3Fcds mid term 3
Fcds mid term 3dalufcds
 
NewcastleGateshead Initiative Partner Update Meeting October 2015
NewcastleGateshead Initiative Partner Update Meeting October 2015NewcastleGateshead Initiative Partner Update Meeting October 2015
NewcastleGateshead Initiative Partner Update Meeting October 2015newcastlegateshead
 
1 q10 conference call presentation
1 q10 conference call presentation1 q10 conference call presentation
1 q10 conference call presentationSantander_ri
 

Viewers also liked (20)

Fluke Test Tools Catalog 2010/2011
Fluke Test Tools Catalog 2010/2011Fluke Test Tools Catalog 2010/2011
Fluke Test Tools Catalog 2010/2011
 
Zend cache evolution.владимир дубина
Zend cache   evolution.владимир дубинаZend cache   evolution.владимир дубина
Zend cache evolution.владимир дубина
 
Lectores y escritores
Lectores y escritoresLectores y escritores
Lectores y escritores
 
TSH - Focusing on Excellence
TSH - Focusing on ExcellenceTSH - Focusing on Excellence
TSH - Focusing on Excellence
 
Competències, canvi curricular i millora educativa: una relació problemàtica
Competències, canvi curricular i millora educativa: una relació problemàticaCompetències, canvi curricular i millora educativa: una relació problemàtica
Competències, canvi curricular i millora educativa: una relació problemàtica
 
Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...
Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...
Business leaders' briefing 12 september 2012 newcastle gateshead initiative f...
 
December 2013- Industry Insights - Leadership survey
December 2013- Industry Insights - Leadership surveyDecember 2013- Industry Insights - Leadership survey
December 2013- Industry Insights - Leadership survey
 
Annotation
AnnotationAnnotation
Annotation
 
Cosmos stanovitsa blizhe
Cosmos stanovitsa blizheCosmos stanovitsa blizhe
Cosmos stanovitsa blizhe
 
St paul's presentation sept 14, 2010
St paul's presentation   sept  14, 2010St paul's presentation   sept  14, 2010
St paul's presentation sept 14, 2010
 
Mod de viata sanatos 2
Mod de viata sanatos 2Mod de viata sanatos 2
Mod de viata sanatos 2
 
Chapter 10 presentation
Chapter 10 presentationChapter 10 presentation
Chapter 10 presentation
 
Struts1+ hibernate3
Struts1+ hibernate3Struts1+ hibernate3
Struts1+ hibernate3
 
Chapter 12 presentation
Chapter 12 presentationChapter 12 presentation
Chapter 12 presentation
 
Exportaciones y Emprendimiento
Exportaciones y EmprendimientoExportaciones y Emprendimiento
Exportaciones y Emprendimiento
 
102 l16 01
102 l16 01102 l16 01
102 l16 01
 
Sujith cv[1][1][1](2)1
Sujith cv[1][1][1](2)1Sujith cv[1][1][1](2)1
Sujith cv[1][1][1](2)1
 
Fcds mid term 3
Fcds mid term 3Fcds mid term 3
Fcds mid term 3
 
NewcastleGateshead Initiative Partner Update Meeting October 2015
NewcastleGateshead Initiative Partner Update Meeting October 2015NewcastleGateshead Initiative Partner Update Meeting October 2015
NewcastleGateshead Initiative Partner Update Meeting October 2015
 
1 q10 conference call presentation
1 q10 conference call presentation1 q10 conference call presentation
1 q10 conference call presentation
 

Similar to Patient and doc engagement online west

why-nih-clinical-research-matters.ppt
why-nih-clinical-research-matters.pptwhy-nih-clinical-research-matters.ppt
why-nih-clinical-research-matters.pptDsoni5
 
Transforming Drug Development at Lilly
Transforming Drug Development at LillyTransforming Drug Development at Lilly
Transforming Drug Development at LillyRahlyn Gossen
 
Pketofast112013 final rev.
Pketofast112013 final rev.Pketofast112013 final rev.
Pketofast112013 final rev.What's the Idea?
 
Protecting Informed Decision Making
Protecting Informed Decision Making Protecting Informed Decision Making
Protecting Informed Decision Making Matthew Katz
 
International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...BBMRI Stakeholder's Forum
 
Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011 Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011 Camp Days
 
Living with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and OpportunitiesLiving with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
 
A Promulgation Of Incredulity In The Pharmaceutical Industry
A Promulgation Of Incredulity In  The Pharmaceutical IndustryA Promulgation Of Incredulity In  The Pharmaceutical Industry
A Promulgation Of Incredulity In The Pharmaceutical IndustryStuart Silverman
 
Patient Portals and Multimedia Reports
Patient Portals and Multimedia ReportsPatient Portals and Multimedia Reports
Patient Portals and Multimedia ReportsThiago Julio, MD
 
ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...
ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...
ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...European School of Oncology
 
Evidence TableEvidence TablePICOT Question[Insert here]APA Sourc
Evidence TableEvidence TablePICOT Question[Insert here]APA SourcEvidence TableEvidence TablePICOT Question[Insert here]APA Sourc
Evidence TableEvidence TablePICOT Question[Insert here]APA SourcBetseyCalderon89
 
Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14
Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14
Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14Douglas Green
 
HIV and Primary Care Transformation baltimore 5 21
HIV and Primary Care Transformation baltimore 5 21HIV and Primary Care Transformation baltimore 5 21
HIV and Primary Care Transformation baltimore 5 21sbromer
 
The Workforce of the Future - Ben Frasier.pdf
The Workforce of the Future - Ben Frasier.pdfThe Workforce of the Future - Ben Frasier.pdf
The Workforce of the Future - Ben Frasier.pdfBenFrasier
 
Meeting healthcare challenges: what are the challenges and what is the role o...
Meeting healthcare challenges: what are the challenges and what is the role o...Meeting healthcare challenges: what are the challenges and what is the role o...
Meeting healthcare challenges: what are the challenges and what is the role o...Mohammad Al-Ubaydli
 
Physicians' social networks in China
Physicians' social networks in ChinaPhysicians' social networks in China
Physicians' social networks in ChinaLen Starnes
 
CHI-and-Onyx-Pharmaceuticals-Oncology-Report
CHI-and-Onyx-Pharmaceuticals-Oncology-ReportCHI-and-Onyx-Pharmaceuticals-Oncology-Report
CHI-and-Onyx-Pharmaceuticals-Oncology-ReportWill Zasadny
 
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceDay 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceCanadian Organization for Rare Disorders
 

Similar to Patient and doc engagement online west (20)

Carlos Henrique Barrios
Carlos Henrique BarriosCarlos Henrique Barrios
Carlos Henrique Barrios
 
why-nih-clinical-research-matters.ppt
why-nih-clinical-research-matters.pptwhy-nih-clinical-research-matters.ppt
why-nih-clinical-research-matters.ppt
 
Transforming Drug Development at Lilly
Transforming Drug Development at LillyTransforming Drug Development at Lilly
Transforming Drug Development at Lilly
 
Pketofast112013 final rev.
Pketofast112013 final rev.Pketofast112013 final rev.
Pketofast112013 final rev.
 
Protecting Informed Decision Making
Protecting Informed Decision Making Protecting Informed Decision Making
Protecting Informed Decision Making
 
International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...International Biobanking: Oportunities and Challenges for Private-Public Coll...
International Biobanking: Oportunities and Challenges for Private-Public Coll...
 
Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011 Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011
 
Virgil Simons
Virgil SimonsVirgil Simons
Virgil Simons
 
Living with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and OpportunitiesLiving with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and Opportunities
 
A Promulgation Of Incredulity In The Pharmaceutical Industry
A Promulgation Of Incredulity In  The Pharmaceutical IndustryA Promulgation Of Incredulity In  The Pharmaceutical Industry
A Promulgation Of Incredulity In The Pharmaceutical Industry
 
Patient Portals and Multimedia Reports
Patient Portals and Multimedia ReportsPatient Portals and Multimedia Reports
Patient Portals and Multimedia Reports
 
ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...
ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...
ABC1 - M. Mayer - Keynote lecture: Living with the Advanced Breast Cancer: Ch...
 
Evidence TableEvidence TablePICOT Question[Insert here]APA Sourc
Evidence TableEvidence TablePICOT Question[Insert here]APA SourcEvidence TableEvidence TablePICOT Question[Insert here]APA Sourc
Evidence TableEvidence TablePICOT Question[Insert here]APA Sourc
 
Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14
Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14
Empowering Healthcare Leaders: The Business Case for Language Access_10.3.14
 
HIV and Primary Care Transformation baltimore 5 21
HIV and Primary Care Transformation baltimore 5 21HIV and Primary Care Transformation baltimore 5 21
HIV and Primary Care Transformation baltimore 5 21
 
The Workforce of the Future - Ben Frasier.pdf
The Workforce of the Future - Ben Frasier.pdfThe Workforce of the Future - Ben Frasier.pdf
The Workforce of the Future - Ben Frasier.pdf
 
Meeting healthcare challenges: what are the challenges and what is the role o...
Meeting healthcare challenges: what are the challenges and what is the role o...Meeting healthcare challenges: what are the challenges and what is the role o...
Meeting healthcare challenges: what are the challenges and what is the role o...
 
Physicians' social networks in China
Physicians' social networks in ChinaPhysicians' social networks in China
Physicians' social networks in China
 
CHI-and-Onyx-Pharmaceuticals-Oncology-Report
CHI-and-Onyx-Pharmaceuticals-Oncology-ReportCHI-and-Onyx-Pharmaceuticals-Oncology-Report
CHI-and-Onyx-Pharmaceuticals-Oncology-Report
 
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceDay 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
 

More from H. Jack West

Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)
Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)
Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)H. Jack West
 
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer MedicineMoving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer MedicineH. Jack West
 
Top 5 highlights in lung cancer, 2014
Top 5 highlights in lung cancer, 2014Top 5 highlights in lung cancer, 2014
Top 5 highlights in lung cancer, 2014H. Jack West
 
Best of ASCO Metastatic Non-Small Cell Lung Cancer
Best of ASCO Metastatic Non-Small Cell Lung CancerBest of ASCO Metastatic Non-Small Cell Lung Cancer
Best of ASCO Metastatic Non-Small Cell Lung CancerH. Jack West
 
10 Key ASCO 2014 Presentations in Lung Cancer
10 Key ASCO 2014 Presentations in Lung Cancer10 Key ASCO 2014 Presentations in Lung Cancer
10 Key ASCO 2014 Presentations in Lung CancerH. Jack West
 
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...H. Jack West
 
What is the value of maintenance therapy in advanced NSCLC, and who should ge...
What is the value of maintenance therapy in advanced NSCLC, and who should ge...What is the value of maintenance therapy in advanced NSCLC, and who should ge...
What is the value of maintenance therapy in advanced NSCLC, and who should ge...H. Jack West
 
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...H. Jack West
 
Inherited T790M EGFR Mutation and Lung Cancer Risk
Inherited T790M EGFR Mutation and Lung Cancer RiskInherited T790M EGFR Mutation and Lung Cancer Risk
Inherited T790M EGFR Mutation and Lung Cancer RiskH. Jack West
 
Key Clinical Implications of how a Cancer Evolves
Key Clinical Implications of how a Cancer EvolvesKey Clinical Implications of how a Cancer Evolves
Key Clinical Implications of how a Cancer EvolvesH. Jack West
 
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...Treating Invisible Disease: How the Probability of Disease We Can't See Chang...
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...H. Jack West
 
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...H. Jack West
 
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and LucanixWest Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and LucanixH. Jack West
 
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...H. Jack West
 
West asco clin mgmt acquired resistance tk is
West asco clin mgmt acquired resistance tk isWest asco clin mgmt acquired resistance tk is
West asco clin mgmt acquired resistance tk isH. Jack West
 
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)H. Jack West
 
West egfr mutation acquired resistance
West egfr mutation acquired resistanceWest egfr mutation acquired resistance
West egfr mutation acquired resistanceH. Jack West
 
West xcenda molec testing sf oct 2011 revised final
West xcenda molec testing sf oct 2011 revised finalWest xcenda molec testing sf oct 2011 revised final
West xcenda molec testing sf oct 2011 revised finalH. Jack West
 
Dr. Jack West Oncology 2.0, to WA AG's Office
Dr. Jack West Oncology 2.0, to WA AG's OfficeDr. Jack West Oncology 2.0, to WA AG's Office
Dr. Jack West Oncology 2.0, to WA AG's OfficeH. Jack West
 

More from H. Jack West (19)

Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)
Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)
Top 10 asco 2016 abstracts for lung cancer (and mesothelioma)
 
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer MedicineMoving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine
 
Top 5 highlights in lung cancer, 2014
Top 5 highlights in lung cancer, 2014Top 5 highlights in lung cancer, 2014
Top 5 highlights in lung cancer, 2014
 
Best of ASCO Metastatic Non-Small Cell Lung Cancer
Best of ASCO Metastatic Non-Small Cell Lung CancerBest of ASCO Metastatic Non-Small Cell Lung Cancer
Best of ASCO Metastatic Non-Small Cell Lung Cancer
 
10 Key ASCO 2014 Presentations in Lung Cancer
10 Key ASCO 2014 Presentations in Lung Cancer10 Key ASCO 2014 Presentations in Lung Cancer
10 Key ASCO 2014 Presentations in Lung Cancer
 
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung C...
 
What is the value of maintenance therapy in advanced NSCLC, and who should ge...
What is the value of maintenance therapy in advanced NSCLC, and who should ge...What is the value of maintenance therapy in advanced NSCLC, and who should ge...
What is the value of maintenance therapy in advanced NSCLC, and who should ge...
 
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide...
 
Inherited T790M EGFR Mutation and Lung Cancer Risk
Inherited T790M EGFR Mutation and Lung Cancer RiskInherited T790M EGFR Mutation and Lung Cancer Risk
Inherited T790M EGFR Mutation and Lung Cancer Risk
 
Key Clinical Implications of how a Cancer Evolves
Key Clinical Implications of how a Cancer EvolvesKey Clinical Implications of how a Cancer Evolves
Key Clinical Implications of how a Cancer Evolves
 
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...Treating Invisible Disease: How the Probability of Disease We Can't See Chang...
Treating Invisible Disease: How the Probability of Disease We Can't See Chang...
 
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Ca...
 
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and LucanixWest Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix
 
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
 
West asco clin mgmt acquired resistance tk is
West asco clin mgmt acquired resistance tk isWest asco clin mgmt acquired resistance tk is
West asco clin mgmt acquired resistance tk is
 
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC)
 
West egfr mutation acquired resistance
West egfr mutation acquired resistanceWest egfr mutation acquired resistance
West egfr mutation acquired resistance
 
West xcenda molec testing sf oct 2011 revised final
West xcenda molec testing sf oct 2011 revised finalWest xcenda molec testing sf oct 2011 revised final
West xcenda molec testing sf oct 2011 revised final
 
Dr. Jack West Oncology 2.0, to WA AG's Office
Dr. Jack West Oncology 2.0, to WA AG's OfficeDr. Jack West Oncology 2.0, to WA AG's Office
Dr. Jack West Oncology 2.0, to WA AG's Office
 

Patient and doc engagement online west

  • 1. CHANGES AFOOT: A NEW MODEL OF INTERACTION BETWEEN DOCTORS AND ENGAGED PATIENTS H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for Advancing Cancer Education (GRACE) www.cancerGRACE.org
  • 2. The Unidirectional Model Requires: •a finite amount of medical information •only the physician having access to it
  • 3. NOBODY Can Keep Up with the Torrent of New Medical Information • Rate of new content more than doubling in last 20 yrs • More & more journals, especially in oncology (>180) (courtesy of Jason Priem/blog) No wonder it feels overwhelming
  • 4.
  • 5. Before and After Molecular Oncology Before After Large populations Small Populations Marginal effects Major benefits Trials in hundreds of sites Trials in very few sites Generally rely on oncologists to enroll May well fall to patients and caregivers to seek out
  • 7.
  • 8. Physicians may be concerned about losing control over the discussion
  • 9. Physicians remain the most trusted source of information about medical issues From Fox, Peer to Peer Healthcare, Pew Internet and American Life Project, 2011
  • 13. Patients are HIGHLY MOTIVATED to help themselves www.CancerGRACE.org a 501(c)3 nonprofit
  • 14. Adapting to a new model: Disruption comes with opportunities • Relationships between patients and physicians are changing • Bidirectional • Physicians no longer expected to know everything out there to know • Patients/caregivers will increasingly turn to social networks and searchable online content www.CancerGRACE.org • Physicians will have a critical role, even if it a 501(c)3 nonprofit changes fundamentally in coming years